2% remdesivir, 39
These three ‘Recovery’ RCTs concluded definitely: (a) that treatment with
What does the best evidence tell us about hydroxychloroquine and dexamethasone? Scott Gavura on August 20, 2020 Tweet Shares With COVID-19 cases continuing to rise, and no
In hospitalized patients with COVID-19-related ARDS, high-dose
(4) Conclusions: In patients hospitalized for COVID-19 in non-intensive
“At 28 days after Español 中文 Tagalog Tiếng Việt 한국어
Taking hydroxychloroquine to treat COVID-19 may increase the risk of heart rhythm problems, blood and lymph disorders, kidney injury, liver problems and failure
Also, hydroxychloroquine doesn't prevent infection with the virus that causes COVID-19
We now know that high-dose hydroxychloroquine is not life-saving in late disease, nor indeed is any antiviral to date, whereas dexamethasone significantly reduces mortality
e
Background: Relatively little is known about the use patterns of potential pharmacologic treatments of COVID-19 in the United States
Introduction
The results also showed that the rate of use of the drug hydroxychloroquine rose to about 42 percent in March 2020 but fell back to near zero the following month, after clinical trial evidence suggested that it was ineffective against COVID-19
A couple of months ago Scott Gavura explained why the veterinary deworming drug ivermectin is the new hydroxychloroquine, a repurposed drug touted as a “miracle cure” for COVID-19 despite evidence that is, at best, very weak and, at worst, supportive of the conclusion that ivermectin is ineffective against COVID-19
Hospitalized patients with Results 17 new, independent meta-analyses of observational studies were conducted that compared hydroxychloroquine, lopinavir-ritonavir, or dexamethasone with an active or placebo comparator for any safety or efficacy outcomes in covid-19 treatment
Only 1% of survivors developed a secondary bacterial infection, yet the median duration of fever in survivors was 12 days and cough persisted for 19 days
Eleven days after announcing the negative results of the RCT on the effectiveness of hydroxychloroquine in COVID-19, Landray and Horby, announced the positive results of the “RCT Recovery” on the effectiveness of dexamethasone in COVID-19 [25, 26]
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the etiological agent of coronavirus disease 2019 (COVID‐19), is an enveloped virus with a positive‐sense single‐stranded ribonucleic acid (RNA) genome